Working... Menu

Expanded Access Treatment Protocol CA204-143

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02368301
Expanded Access Status : Approved for marketing
First Posted : February 23, 2015
Last Update Posted : October 6, 2016
Information provided by (Responsible Party):
Bristol-Myers Squibb

Tracking Information
First Submitted Date February 6, 2015
First Posted Date February 23, 2015
Last Update Posted Date October 6, 2016
Descriptive Information
Brief Title Expanded Access Treatment Protocol CA204-143
Brief Summary The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.
Detailed Description Not Provided
Study Type Expanded Access
Intervention Drug: Elotuzumab in combination with Lenalidomide and Dexamethasone
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status Approved for marketing
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Puerto Rico,   United States
Removed Location Countries  
Administrative Information
NCT Number NCT02368301
Responsible Party Bristol-Myers Squibb
Study Sponsor Bristol-Myers Squibb
Collaborators Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
PRS Account Bristol-Myers Squibb
Verification Date October 2016